Cystatin C-based eGFR for drug dosing

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

1 post / 0 new
Log in or register to post comments
Wed, 07/27/2022 - 16:03
#1
Daniel Kudryashov
Daniel Kudryashov's picture
Offline
Last seen: 1 month 4 weeks ago
Joined: 07/26/2018 - 19:27
Cystatin C-based eGFR for drug dosing

Our nephrology team is encouraging a shift towards Cystatin C-based eGFR for drug dosing. One of our concerns is around practicing "off-label" since most FDA approved dosing is based on CrCl cut-offs. Has this been evaluated at your institution? Please select the options that match your practice, and feel free to expand upon your response in comments:

1) Serum cystatin C (Scys)-based eGFR is used for renal drug adjustment in place of Serum Creatinine (SCr)-based eGFR

2) Scys eGFR is used for renal drug adjustment in place of SCr eGFR only in specific patient populations (please define)

3) Scys eGFR is used for confirmatory purposes in addition to SCr eGFR to help guide diagnosis and treatment based on provider discretion on case by case basis

4) Scys eGFR is not used for renal drug adjustment

5) Any other comments: _____

Thank you.
Daniel Kudryashov
Keck Medicine of USC

Top